Realiza tu consulta
Recomendar a un paciente
921 13 00 04

Notamos que estás en nuestra página de España (ES). ¿Quieres cambiar de país? Elije entre las opciones:

UK
AU
Centros
Médicos
921 13 00 04
Realiza tu consulta
Recomendar a un paciente

Notamos que estás en nuestra página de España (ES). ¿Quieres cambiar de país? Elije entre las opciones:

UK
AU
Centros
Médicos
921 13 00 04
2023-01-29T10:00:00.000+11:00

PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?

PSMA PET/CT imaging for biochemical recurrence of prostate cancer after radiotherapy: is it necessary to review the Phoenix criteria?
Clinical and Translational Imaging (2023) https://doi.org/10.1007/s40336-023-00543-x
/es/profesionales-sanitarios/estudios-e-investigacion/publicacion-de-articulos/psma-pet-ct-imaging-for-biochemical-recurrence-of-prostate-cancer-after-radiotherapy-is-it-necessary-to-review-the-phoenix-criteria
Oncología Radioterápica
Written by Elías Gomis Sellés, Antonio Maldonado, Eva-Maria Triviño-Ibañez, Nuria Azahara Linares Mesa, Noelia Sanmamed Salgado, Rocio del Castillo Acuña, Jeremie Calais, Amar U. Kishan, Antonio Rodriguez Fernandez, Manuel Recio Rodriguez, José Daniel Subiela, Fernando Lopez Campos, Felipe Couñago
Elías Gomis Sellés, Antonio Maldonado, Eva-Maria Triviño-Ibañez, Nuria Azahara Linares Mesa, Noelia Sanmamed Salgado, Rocio del Castillo Acuña, Jeremie Calais, Amar U. Kishan, Antonio Rodriguez Fernandez, Manuel Recio Rodriguez, José Daniel Subiela, Fernando Lopez Campos, Felipe Couñago:::

 

Abstract

PSMA positron emission tomography (PET)/CT imaging and new systemic treatment strategies have been recently implemented in the routine care of patients with prostate cancer. In the new era of PSMA PET/CT imaging, the definition of recurrence as established by the Phoenix criteria may be questioned.

 

Conclusion

The development of PSMA PET/CT questions the need for a review of the Phoenix criteria. Solid studies are needed to evaluate new PSA thresholds to redefine these criteria considering the clinical benefit to the patient of changing the therapeutic approach at different stages of the disease.

 

https://link.springer.com/article/10.1007/s40336-023-00543-x